PredxBio

Access our brand new White Paper here

Menu

Press Releases

April 28, 2025

PredxBio and Hamamatsu Photonics Announce Strategic Partnership to Deliver Next-Generation Spatial Biology Solutions for Cancer Research and Therapeutic Development

PredxBio, a pioneer in AI-powered spatial biomarker discovery, today announced a strategic collaboration with Hamamatsu Photonics K.K., a global leader in imaging technologies. The partnership unites Hamamatsu’s advanced MoxiePlex™ multiplex immunofluorescence imaging system with PredxBio’s SpaceIQ™ spatial analytics platform to deliver an integrated workflow tailored to basic and translational research tailored to immuno-oncology.

Read More

April 25, 2025

PredxBio Launches Enhanced SpaceIQ™ Platform with Multiomic Spatial Capabilities Ahead of AACR 2025

PredxBio today announced the official launch of enhanced SpaceIQ™ platform to integrate brightfield, spatial proteomics and transcriptomics datasets to deliver a unified, high-resolution view of the tumor microenvironment—unlocking new insights into cellular interactions, immune architecture, and mechanisms of therapeutic response and resistance. This milestone launch, timed ahead of the American Association for Cancer Research (AACR) Annual Meeting 2025, will be highlighted by two scientific poster presentations and a spotlight symposium at the conference. The new capabilities of SpaceIQ™ are poised to accelerate insights in cancer biology, improve patient stratification, and drive advances in precision immuno-oncology.

Read More

April 23, 2025

Turning Discovery into Deployment: PredxBio and A/Prof Arutha Kulasinghe from The University of Queensland Introduce Predictive Test Framework for Spatial Biomarkers

PredxBio, an industry leader in explainable AI and spatial biology, in partnership with Associate Professor Arutha Kulasinghe and the Queensland Spatial Biology Centre, today announced a key advancement in the translation of high-plex spatial data into robust, and clinically deployable predictive biomarkers for precision oncology.

Read More

October 22, 2024

PredxBio Announces Collaboration with University of Queensland’s Dr. Arutha Kulasinghe and the Queensland Spatial Biology Centre

PredxBio is excited to announce a collaboration with Dr. Arutha Kulasinghe, PhD, of the University of Queensland (UQ), and the Queensland Spatial Biology Center (QSBC). This partnership aims to unlock actionable biology from immunotherapy studies, with the goal of developing a highly selective, spatial-biomarker-based companion diagnostic for predicting immunotherapy response.

Read More

April 9, 2024

PredxBio and PictorLabs Forge Strategic Partnership to Advance Cancer Research and Diagnostics with Next Generation Spatial Analytics

PredxBio, Inc., a leader in spatially intelligent biology, and PictorLabs, Inc., a leading digital pathology firm pioneering AI-powered virtual staining technology, are pleased to announce a transformative partnership aimed at revolutionizing cancer research, diagnosis, and treatment.

Read More

April 7, 2024

PredxBio Unveils Revolutionary SpaceIQ™ Platform Ushering in a New Era of Spatial Multi-Omics at 2024 AACR Annual Meeting

PredxBio, a leading technology company for spatial biology solutions, is set to make waves at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, taking place from April 7th to 11th. Attendees are invited to explore PredxBio Booth #952, where PredxBio will unveil its groundbreaking SpaceIQ™ platform, poised to redefine cancer research and patient care. In addition to the SpaceIQ platform, PredxBio will highlight its recent partnerships and growing ecosystem, demonstrating its commitment to collaborative innovation in cancer research and therapy development.

Read More

April 2, 2024

PredxBio and Sirona Dx Join Forces to Revolutionize Drug Discovery and Development with SpaceIQ™ Leveraging Advanced Spatial Analytics and Explainable AI Solutions

PredxBio, Inc., a leader in spatially intelligent biology, and Sirona Dx, a leader in single cell multi-omics, analytical services, have announced a strategic partnership aimed at reshaping the landscape of drug discovery and development. This collaboration marks a pivotal moment in the industry, leveraging Explainable AI-Driven Spatial Biology with a groundbreaking new platform SpaceIQ™ to unlock the potential of genomic, proteomic, and transcriptomic data through advanced spatial analytics.

Read More

February 15, 2024

PredxBio Appoints Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors

PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression and response to therapy, proudly announces the appointment of Stanley M. Marks, M.D., Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors.

Read More

January 4, 2024

Revolutionizing Spatial Biology: PredxBio to Showcase their Cutting-Edge Innovations at JP Morgan Healthcare Week

PredxBio, a pioneering force in spatial biology, today announces its participation in the DigiMed Showcase taking place during JP Morgan Healthcare Week. B. Dusty Majumdar, PhD, the CEO of PredxBio, will present the company’s revolutionary solutions live on Monday, January 08, 2024, at 9:45 AM (PT). The presentation will delve into PredxBio’s cutting-edge solutions, showcasing how the company is shaping the future of cancer care through spatially intelligent biology, utilizing unbiased Spatial Analytics and Explainable AI.

Read More

June 14, 2023

PredxBio Appoints Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, to its Board of Directors, Strengthening Expertise in Oncology and Precision Medicine

PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression, is pleased to announce the addition of Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, to its Board of Directors.

Read More

June 7, 2023

PredxBio Strengthens Leadership Team with Appointment of Brad Spitz as Chief Commercial Officer

PredxBio, the leading company in Spatial Biology and Explainable AI for predicting the progression of disease has announced the appointment of Brad Spitz, MBA, as its Chief Commercial Officer. In this role, Brad will drive the company’s commercial growth strategy, lead global sales and business development efforts, and further expand PredxBio’s presence in the biopharma industry.

Read More

April 17, 2023

PredxBio is bending the survival curve for immunotherapy cancer patients with spatially intelligent biology at AACR 2023

PredxBio (formerly SpIntellx) announces that it will attend the 2023 Annual Meeting of American Association for Cancer Research in Orlando, April 15-19, Booth #974 and Poster #5445 to present their explainable AI-powered unbiased spatial analytics platform, that seamlessly integrates multimodal data to unravel the hidden circuitries of the tumor microenvironment and reveal the complex network biology of the cancer…

Read More

April 4, 2023

SpIntellx Rebrands as PredxBio to Unlock Spatial Biology Insights with Explainable AI

SpIntellx, the leader in Spatial Biology leveraging Explainable AI for predicting the progression of disease, announced today its rebranding as PredxBio (pronounced, “pre-dix-bio”). The PredxBio platform is designed to empower drug discovery, translation, and clinical trials, initially focusing on immuno-oncology space…

Read More

August 18, 2022

PredxBio and iCura Diagnostics Partner to Expand Access to Advanced Spatial Analytics and Explainable AI Products for Pathology and Oncology Research

PredxBio, Inc., a leader in spatially intelligent biology and iCura Diagnostics, a leading contract research organization focused on capitalizing multiomic data to accelerate end-to-end clinical workflow solutions and biomarker discovery, have announced a partnership to transform precision oncology through unlocking the power of genomic, proteomics, and transcriptomic data using advanced spatial analytics…
Read More

JULY 18, 2022

PredxBio and Inspirata Announce New Technical Partnership and Integration to Expand Access to Next Generation Explainable AI Software for Breast Biopsies

PredxBio, Inc., and Inspirata have announced that they will collaborate to integrate the PredxBio HistoMapr-Breast™ platform and Inspirata’s Dynamyx® software into one seamless solution. HistoMapr-Breast is the one and only computational pathology software that taps the power of explainable artificial intelligence (xAI) for healthcare providers to diagnose, prognosticate and treat breast cancer more efficiently and accurately…
Read More

MAY 16, 2022

PredxBio Appoints Industry Leader B. Dusty Majumdar, Ph.D. as Chief Executive Officer to Spearhead the Next Phase of Growth

B. Dusty Majumdar, Ph.D. has been appointed as the Chief Executive Officer (CEO) of PredxBio, Inc., a precision pathology company whose mission is focused on dramatically improving patient outcomes fueled by proprietary unbiased spatial analytics and explainable AI. Dr. Majumdar, is a seasoned leader in Precision Healthcare with more than 20 years of experience in building and successfully launching innovative technologies across diagnostic imaging, oncology, multi-omics,…
Read More

APRIL 05, 2022

PredxBio is ushering a new era of unbiased spatial analytics and explainable AI in precision pathology at AACR 2022

PredxBio, Inc. created the new era of precision pathology to dramatically improve patient outcomes by leveraging proprietary unbiased spatial analytics and explainable AI. PredxBio’s precision pathology solutions have the potential to unlock a plethora of new applications in medicine and research by answering the fundamental question “Why?” , thus revealing the underlying patient-specific disease network biology across each stage of the drug development, diagnostics, and treatment pipelines…
Read More

MARCH 18, 2022

PredxBio announces the new era of precision pathology at USCAP 2022

PredxBio, Inc. created the new era of precision pathology to dramatically improve patient outcomes by leveraging proprietary unbiased spatial analytics and explainable AI that answers the question “Why?” to reveal the underlying patient-specific disease network biology, across each stage of the drug development, diagnostic and treatment pipelines. PredxBio offers software as a service (SaaS) for precision pathology applications harnessing unbiased spatial analytics and explainable AI including: accelerated drug discovery for identifying novel targets, biomarkers and “invisible” cell types; optimized clinical trials for precision patient stratification;…
Read More

JUNE 14, 2021

Meet the 7 life science startups of AlphaLab Health’s inaugural accelerator cohort

Seven promising life science startups started off 2020 with a shot of support from two of the region’s health and economic development-minded orgs. Launched in September 2020, AlphaLab Health is an initiative of Innovation Works, which also runs the AlphaLab and AlphaLab Gear accelerator programs, and Allegheny Health Network. Those selected for the program’s cohorts receive early-stage funding of up to $100,000, access to mentorship and clinical expertise through AlphaLab’s network,…
Read More

JULY 20, 2020

PredxBio and CellNetix Collaborate to Validate HistoMapr-Breast™, an Explainable AI Software Platform Featuring Advanced Spatial Analytics to Provide Intelligent Guides for Pathology Laboratories

PredxBio, Inc., and CellNetix Pathology & Laboratories have announced that they will collaborate to validate the PredxBio HistoMapr-Breast™ Platform, which taps the power of explainable artificial intelligence (xAI) for healthcare providers to diagnose and treat breast cancer more efficiently and accurately…
Read More

DECEMBER 17, 2019

Innovations in Artificial Intelligence, Cloud, Blockchain, and Analytics, 2019: Advances in AI, Blockchain, and Business Intelligence - ResearchAndMarkets.com

This edition of IT, Computing and Communications (ITCC) TechVision Opportunity Engine (TOE) provides a snapshot of the emerging ICT led innovations in artificial intelligence, machine learning, cloud, and analytics. This issue focuses on the application of information and communication technologies in alleviating the challenges faced across industry sectors in areas such as banking, oil & gas, healthcare, life sciences, and industrial sectors…
Read More

Subscribe to our Newsletter

* indicates required

We received your request! One of our team members will be in touch as soon as possible.

Submit your Resume

Download Whitepaper

Download Whitepaper

B. Dusty Majumdar, PhD

CHIEF EXECUTIVE OFFICER

Linkedin-in

B. Dusty Majumdar, PhD  is a seasoned leader in Precision Healthcare with more than 20 years of experience in building and successfully launching innovative technologies across oncology, multi-omics, Real-World Evidence (RWE). diagnostic imaging and liquid biopsy platforms leveraging some of the industry’s most advanced AI platforms, genomic and clinical simulations (digital twins), and emerging medical imaging technologies. Dr. Majumdar’s experience includes leading strategy and marketing as the Chief Marketing Officer (CMO) at IBM and multiple commercial and technical leadership roles at GE Healthcare, Exact Sciences and 3M. He has also led the commercial and strategic functions in a range of start-ups in the healthcare/biopharma space over the last few years.  Dr. Majumdar is a widely respected global leader in the healthcare industry and holds a Ph.D. from the University of Texas at Austin and a bachelor’s degree from the Indian Institute of Technology (IIT), Kharagpur.  He has authored several peer-reviewed scientific publications and holds multiple patents.

Joe Camaratta

Sr. VP Business Development

Linkedin-in

Joe Camaratta specializes in medical technology innovation and commercialization, taking products from concept to clinical adoption. He held executive positions for GE Healthcare and Siemens Healthcare and built businesses in medical imaging, cardiology, and oncology. He founded and led two early stage medical technology companies that apply artificial intelligence to improve clinical decision-making.

Joe holds a Master of Science degree in Computer Science from Rutgers University and a Bachelor of Science degree in Computer Science from Drexel University. He currently serves as an advisor to the Entreprenuerial Investing Program of the Crohn’s & Colitis Foundation, and the University Science Center QED Program focused on commercialization of academic innovations

Bruce Campbell, MS

VP Software Engineering

Linkedin-in

Bruce leads the software engineering and quality assurance teams at PredxBio. As the VP of Software Engineering, he is responsible for analytical infrastructure, product development and the commercialization of machine learning, image processing, and computational biology algorithms. Prior to joining PredxBio, Bruce was at IBM and Xylem in global Director of Data Science roles. He has over 20 years of experience in digital pathology algorithms and is highly motivated to deliver care through digital and computational pathology. He has multiple successful FDA 510k device applications, and multiple CLIA certified algorithms deployed in clinical practice.

Bruce holds a BS in Physics and MS in Applied Mathematics from the University of Rochester, an MS in Statistics from North Carolina State University, and is currently pursuing graduate mathematics studies at The Ohio State University. Bruce loves the outdoors. You can find him hiking and rock climbing in Appalachia.